NordiTamox 20mg/tab 50 Tabletten by Nordi Pharma

Usage

1. Obtain pre-PCT blood work including serum total testosterone, LH, FSH, and estradiol — these baseline values determine your programme's target duration before the first tablet is consumed.
2. Calculate your expected suppression tier (low / moderate / high) based on the number of compounds used, cycle duration, and dosage levels, and set an initial PCT length target of 4, 8, or 12 weeks accordingly.
3. Begin NordiTamox at 40 mg/day (two tablets) for the first two weeks if suppression is moderate-to-high, or at 20 mg/day from day one if suppression was minimal and a shorter programme is planned.
4. Retest blood markers at the end of week 4 and again at week 6 or 8 — if LH, FSH, and testosterone have not returned to pre-cycle reference ranges, extend the programme by two-week increments rather than stopping on schedule.
5. Once two sequential blood draws — taken one week apart — confirm testosterone consistently above 400 ng/dL with recovering gonadotropin values, begin a structured dose taper rather than abrupt cessation.
6. Record each week's dosing and any subjective markers (libido, energy, mood) alongside blood-work results; this data establishes a personal duration profile that informs safer planning for any future cycle.

Warnings

Frequently asked questions

How many weeks should a complete post-cycle therapy programme last?

PCT length ranges from four weeks for minimally suppressive single-compound cycles to twelve weeks for heavily suppressive multi-compound protocols. The determining factor is suppression depth, not cycle length alone. A four-to-six-week programme suits moderate single-compound users; eight-to-twelve weeks is appropriate when gonadotropin output has been significantly compressed. Blood work at the end of each phase is the only reliable guide to whether additional weeks are needed.

Can running Tamoxifen Citrate for too long actually cause problems?

Yes — sustained SERM exposure beyond physiological need suppresses IGF-1 secretion, negatively shifts HDL/LDL ratios, and increases the likelihood of visual disturbances (phosphene or blurred vision) in predisposed individuals. Once serum testosterone and gonadotropin values reach pre-cycle reference ranges on two consecutive blood draws, continuing Tamoxifen Citrate offers no additional recovery benefit and introduces unnecessary risk. A structured dose taper before discontinuation reduces rebound effects.

Under what circumstances can PCT be shortened to fewer than four weeks?

Shortening PCT below four weeks is physiologically justified only when cycle duration was brief (under six weeks), androgen exposure was low, and pre-cycle blood work confirmed robust baseline testosterone. Even then, a minimum of three weeks is generally advised to allow gonadotropin pulsatility to re-establish. Attempting two-week protocols without blood-work confirmation risks incomplete recovery, leaving testosterone significantly below baseline and increasing the probability of post-PCT fatigue and libido suppression.

How does the 20 mg tablet strength of NordiTamox benefit a variable-length PCT?

The 20 mg tablet denomination is the highest unit dose in this product category, covering a standard daily maintenance dose in a single whole tablet. When duration needs to be extended — say from six to ten weeks based on blood work — the same tablet format functions without splitting or dose recalculation, maintaining API delivery accuracy throughout any programme length. This consistency matters because tablet-splitting introduces content variance of up to 15 % per half-dose.

Does the 50-tablet pack size of NordiTamox support longer PCT programmes without reordering?

A 50-tablet pack of 20 mg tablets provides 1,000 mg of Tamoxifen Citrate total. At a standard 20 mg/day maintenance dose, that covers ten full weeks uninterrupted. For a front-weighted protocol using 40 mg/day in weeks one and two (fourteen tablets) and 20 mg/day thereafter, the pack sustains an eight-week complete programme with tablets remaining for an optional taper week — making mid-protocol reordering unnecessary for the majority of duration scenarios. (2) angle_used

Manufacturer

Nordi Pharma's quality architecture for NordiTamox rests on a production philosophy that treats tablet-stage analytical release as the definitive checkpoint — not a supplementary step. Each finished-tablet batch is subjected to HPLC quantification against a certified Tamoxifen Citrate reference standard, with results documented in batch-specific certificates of analysis that confirm the declared 20 mg per tablet content survived compression and excipient integration intact. Separately, LAL endotoxin screening is applied at the finished-tablet stage — a practice more commonly associated with injectable release criteria than solid-dose manufacturing, and one that reflects Nordi Pharma's decision to set its solid-dose release threshold above the sector norm. Distributors and end users receive access to batch documentation upon request, a transparency commitment that positions the brand within a verifiable quality tier rather than relying on reputation unsupported by data.